Detalles de la búsqueda
1.
Correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer: an FDA pooled analysis.
Lancet Oncol
; 25(4): 455-462, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38458207
2.
Impact of Increasing PD-L1 Levels on Outcomes to PD-1/PD-L1 Inhibition in Patients With NSCLC: A Pooled Analysis of 11 Prospective Clinical Trials.
Oncologist
; 29(5): 422-430, 2024 May 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38349736
3.
FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer.
Oncologist
; 26(5): 433-438, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33687763
4.
Does Knowledge of Treatment Assignment Affect Patient Report of Symptoms, Function, and Health Status? An Evaluation Using Multiple Myeloma Trials.
Value Health
; 24(6): 822-829, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34119080
5.
FDA Accelerated Approval of Pembrolizumab for Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma.
Oncologist
; 25(7): e1077-e1082, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32272501
6.
Analyzing patient-reported outcome data when completion differs between arms in open-label trials: an application of principal stratification.
Pharmacoepidemiol Drug Saf
; 28(10): 1386-1394, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31410963
7.
FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond.
Oncologist
; 22(11): 1392-1399, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28835513
8.
Use of External Control Cohorts in Pediatric Brain Tumor Clinical Trials.
J Clin Oncol
; 42(12): 1340-1343, 2024 Apr 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38394473
9.
FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum.
Clin Cancer Res
; 30(1): 23-28, 2024 01 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37624421
10.
FDA Approval Summary: Dabrafenib in Combination with Trametinib for BRAFV600E Mutation-Positive Low-Grade Glioma.
Clin Cancer Res
; 30(2): 263-268, 2024 01 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-37610803
11.
FDA Approval Summary: Atezolizumab as Adjuvant Treatment following Surgical Resection and Platinum-Based Chemotherapy for Stage II to IIIA NSCLC.
Clin Cancer Res
; 29(16): 2973-2978, 2023 08 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-36951523
12.
The Association Between Baseline Hepatic or Renal Function and Clinical Outcomes for Patients With Non-Small Cell Lung Cancer Treated With a PD-1/PD-L1 Blocking Antibody Using Real-World and Trial Data.
Clin Pharmacol Ther
; 113(5): 1139-1149, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36790088
13.
FDA Approval Summary: Amivantamab for the Treatment of Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.
Clin Cancer Res
; 29(17): 3262-3266, 2023 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37022784
14.
Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma.
JHEP Rep
; 5(6): 100747, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37197442
15.
FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement.
Clin Cancer Res
; 29(5): 838-842, 2023 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36206041
16.
FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors.
Clin Cancer Res
; 29(18): 3573-3578, 2023 09 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37265412
17.
FDA Approval Summary: Mobocertinib for Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.
Clin Cancer Res
; 29(3): 508-512, 2023 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36112541
18.
FDA Approval Summary: Nivolumab for the Adjuvant Treatment of Adults with Completely Resected Esophageal/Gastroesophageal Junction Cancer and Residual Pathologic Disease.
Clin Cancer Res
; 28(24): 5244-5248, 2022 12 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35960160
19.
FDA Approval Summary: Nivolumab in Combination with Ipilimumab for the Treatment of Unresectable Malignant Pleural Mesothelioma.
Clin Cancer Res
; 28(3): 446-451, 2022 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34462287
20.
FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC.
Clin Cancer Res
; 28(8): 1482-1486, 2022 04 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-34903582